KPV Peptide Dosage Chart: Units, Timing, Route

The KPV Dosage Chart

A dosage chart normally summarizes what trials established. KPV has no trials to summarize. The FDA staff review that preceded the July 2026 advisory vote searched PubMed, Embase, ClinicalTrials.gov, and the rest of the standard databases and reported no data on KPV given to humans by any route. So the honest version of a KPV dosage chart has two halves: the numbers that circulate on research-market sites, which nobody validated, and the one number a licensed provider actually prescribes through PeRx, from a pharmacy-set concentration a medical director approved. Here are both, side by side.

The bottom row is the one to hold onto. The research-market figures in the middle are not wrong so much as unmoored: vendors need a serving size on the label, and the numbers were scaled from animal work by intuition rather than pharmacokinetics. The PeRx figure is different in kind, not just in provenance. It is one component of a fixed-concentration blend, reviewed and approved as written, and the full context for that blend lives in the KLOW guide Read nextKLOW Peptide: The Complete GuideKLOW packs four repair peptides into one prescribed vial: BPC-157, GHK-Cu, KPV, and TB-500. This guide covers what each one contributes, what the research actually supports, what a six-week cycle looks like in practice, and how the prescribed vial differs from the research-site blends that dominate search results.Read article . For the molecule itself, What Is KPV Read nextKPV Peptide Benefits: What It Is & How It WorksKPV is three amino acids long, which makes it one of the smallest molecules anyone calls a peptide. Search interest in KPV peptide benefits has grown far faster than the evidence has, and almost none of the literature behind those benefit claims involves humans. Here is what is actually known, what the research supports and does not, why PeRx only supplies KPV inside a four-peptide blend, and what the July 2026 FDA panel vote did and did not do.Read article covers the alpha-MSH fragment story properly.

KPV Morning or Night?

This is one of the most searched KPV questions, and the literature gives it a short answer: nothing known about KPV cares what time it is. Some peptides have real circadian logic; growth hormone secretagogues are timed to the sleep-onset GH pulse, and injecting them at breakfast wastes the mechanism. KPV has no equivalent. There are no published human pharmacokinetics at all, so no half-life data, no absorption curve, and no evidence that a morning dose behaves differently from an evening one.

The KLOW prescription reflects that. It does not name a time of day, and the omission is deliberate. What it asks for instead is consistency: pick an hour you can hit five days a week and keep it. In practice most patients land on the morning, for logistics rather than biology. The KLOW instructions flag brief lightheadedness as a possibility after injection and suggest sitting for a few minutes afterward, which is easier to build into a morning routine than into the end of a long day. Evening works exactly as well if that is when you are reliably home. Fasted or fed makes no difference for a subcutaneous injection, so meal-timing rules do not apply here.

Dosage Per Day: What Circulates vs What Is Prescribed

Ask the internet how much KPV to take per day and the modal answer is 250 to 500 mcg, sometimes split into two servings, usually attached to an oral product. Trace that number back and it dead-ends at vendor pages citing each other. The mouse colitis studies dosed KPV by animal weight or in drinking water, in amounts that do not convert cleanly to a human serving, and no human study exists to anchor the range. That does not make half a milligram dangerous; the FDA also noted a FAERS search through December 3, 2025 returned no KPV adverse event reports at all. It makes it unverified: a number with no data behind it cannot be right or wrong, only repeated.

The prescribed answer is more concrete. On the PeRx protocol your KPV dose per day is 0.6 mg, five days a week, delivered inside a 20-unit draw of KLOW. Saturday and Sunday you take nothing. Over a week that is 3 mg of KPV; over the full 6-week course, 18 mg, after which the prescription requires 6 weeks off. The daily figure never titrates. Day one and day thirty are the same draw, there is no loading phase, and drawing more units does not make anything heal faster. It just raises your exposure to all four peptides in the blend at once.

Oral KPV vs Injected KPV

Oral KPV is not an internet invention. It is the route the most-cited KPV research actually used. In the 2008 Gastroenterology study, Dalmasso and colleagues showed that KPV enters intestinal cells through PepT1, a transporter that ferries small peptides across the gut lining and gets induced in the colon during bowel inflammation. Mice with chemically induced colitis that drank KPV in their water developed less inflammation. The oral route was the point: the target was the gut wall itself, and the transporter concentrated the tripeptide exactly where the damage was.

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134(1):166-178. View study

Kannengiesser and colleagues reproduced the anti-inflammatory signal the same year in two further mouse colitis models, which is why oral KPV became the gut-protocol darling of the research market and why capsule products exist at all. But the oral story has a second chapter the vendor pages skip. By 2017, researchers trying to make oral KPV work for colitis were wrapping it in hyaluronic-acid-functionalized nanoparticles, because plain KPV taken by mouth largely fails to survive the trip in useful amounts. A delivery system that elaborate is an admission about the plain capsule.

Xiao B, Xu Z, Viennois E, et al. "Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis." Molecular Therapy. 2017;25(7):1628-1640. View study

Injection sidesteps the delivery problem for systemic purposes. A subcutaneous dose does not have to survive the stomach; it enters circulation from the injection site, which is the rationale for injected KPV in repair-oriented protocols where the target is not the gut lumen. To be precise about routes, since KPV research spans several: the published animal work is mostly oral and topical, the FDA nomination was for a topical cream and gel, and PeRx supplies KPV one way only, as a subcutaneous injection inside KLOW. Nothing PeRx dispenses is an oral KPV capsule, a topical, or a nasal spray, and no PeRx product of any kind is intranasal. Oral KPV remains a research-market product for gut-focused use, sold without a prescription, standardized content, or a single human trial behind its serving sizes. If your interest in KPV is a diagnosed bowel condition, that is a conversation for your gastroenterologist, not a capsule order.

How KPV Is Dosed Inside KLOW

KLOW is compounded at 3 mg of KPV per mL, alongside 3 mg BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide , 10 mg GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide , and 3 mg TB-500 in the same mL. Every KPV number on this page falls out of that concentration and the 20-unit dose. Twenty units on a U-100 insulin syringe is 0.2 mL, and 0.2 mL of a 3 mg/mL solution carries 0.6 mg of KPV. Five doses a week is 1 mL, so your weekly KPV intake equals the per-mL label figure, 3 mg. Thirty doses over six weeks is 18 mg. The 5 mL vial holds 25 doses, five weeks, so a full course runs into a second vial. The same arithmetic for all four peptides at once lives in the KLOW dosage guide Read nextKLOW Peptide Dosage: Chart, Frequency, CycleNearly every KLOW dosage chart online describes an 80 mg research vial that someone mixes at their kitchen table. The KLOW a physician actually prescribes is a different product with different math. This is the dosing as written on the PeRx prescription: units on the syringe, days per week, weeks per cycle, and what the gray-market charts get wrong.Read article ; this page keeps the spotlight on the KPV line.

Why a blend rather than a standalone KPV vial? Partly clinical intent: the KLOW protocol is written for tissue repair, where KPV contributes the inflammatory-signaling arm while BPC-157, TB-500, and GHK-Cu cover the repair and remodeling work. Partly practical reality: KPV on its own has no established human dose to prescribe, so it rides a protocol a pharmacy and a medical director defined as a whole, at a fixed ratio, with screening questions specific to each component. The injection goes subcutaneously as close to the injury site as possible, rotating spots; Where to Inject KLOW Read nextWhere to Inject KLOW: Injury Site and RotationKLOW carries a placement instruction most peptides do not: the dose goes as close to the injury site as possible. Four peptides share one vial, and you still have to rotate. Here is how those two instructions fit together in practice.Read article maps that out, and How to Take Peptides Read nextHow to Take Peptides: Injection, Capsule, or StripMost prescription peptides are injected under the skin, a few are swallowed, and a small category dissolves under the tongue. This is the route-of-administration hub: why the route matters, exactly how a subcutaneous injection works, when each peptide is usually taken, what arrives in a PeRx kit, and a directory of per-peptide injection-site guides.Read article covers first-injection basics. What the dose does not respond to is the July 2026 regulatory news. The FDA advisory committee that recommended KPV for the 503A bulks list on July 23, 2026, by 8 votes to 6, reviewed eligibility for compounding, not dosing, and the vote remains non-binding with no rule issued as of September 8, 2026. Our write-up of the panel Read nextFDA Panel Backs 6 of 7 Peptides, Rejects DSIPThe FDA's Pharmacy Compounding Advisory Committee finished its two-day meeting on July 24, 2026. By the end, it had voted to recommend six of the seven peptides on the agenda for the 503A compounding list, including BPC-157, TB-500, MOTS-C, Semax, and Epitalon, and against just one, Emideltide (DSIP). Every vote went against the FDA's own scientists. Here is the full tally, what it changes, and what it does not.Read article has the full tally.

Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases." Endocrine Reviews. 2008;29(5):581-602. View study

KLOW

The only way PeRx dispenses KPV: a four-peptide blend of BPC-157, GHK-Cu, KPV, and TB-500, compounded by a US-based 503A pharmacy at a fixed 3/10/3/3 mg per mL. It ships fully reconstituted and ready to use, refrigerated, with insulin syringes and swabs in the box.

One 20-unit draw delivers all four peptides, 0.6 mg of it KPV, with no mixing step and no concentration math. $349 per vial, prescribed by a licensed provider after screening.

KPV arrives as one of four peptides in a single ready-to-use vial.

Shop Now

If You Miss a Dose

The rule is calendar-based and forgiving. If you remember on the same day, take the dose when you remember. If the day has passed, skip it entirely and take your next scheduled dose on the next dosing day. Never inject twice to make up ground: doubling a KLOW draw doubles your exposure to KPV and three other peptides in one sitting, for zero documented benefit. One missed weekday in a 30-dose course changes nothing worth correcting.

A weekend is not a missed dose. Saturday and Sunday off is the schedule as written, so there is nothing to compensate for on Monday. If you forget doses regularly, fix the anchor rather than the dose: tie the injection to something you already do at the same time five days a week, and the problem usually disappears. And if you stopped for several days because something felt wrong, a rash, hives, a site reaction that lingers, do not quietly restart. That is a message to the care team first, and the KPV side effects guide Read nextKPV Peptide Side Effects: What Is Actually KnownKPV has never been given to a human in a published study, which makes every side-effect list you find online a work of extrapolation. Here is what the animal research shows, an honest answer to the cancer question, what is and is not known about the liver, and why this alpha-MSH fragment does not tan your skin.Read article covers what is worth reporting and what is routine.

Common Questions